

1 November 2018

Felix Swadel

Via email: fyi-request-8816-b7675c2a@requests.fyi.org.nz

Dear Felix

REQUEST FOR INFORMATION

Thank you for your request dated 5 October 2018 under the Official Information Act 1982 (OIA). You asked for any data or estimates available relating to the cost of the funded medicine (emtricitabine with tenofovir disoproxil fumarate) used for pre-exposure prophylaxis (PrEP). This information is provided in the table below, and covers the period 1 March 2018 to 31 July 2018.

Cost of funded emtricitabine with tenofovir disoproxil fumarate (Truvada) for PrEP

	Gross Cost	Number of patients
Emtricitabine with tenofovir disoproxil fumarate (Truvada) for PrEP	\$3,416,774.47	818

Please note that the gross cost refers to the manufacturer's price, which is the price at which the supplier supplies a pharmaceutical to the New Zealand market. This does not include GST and any mark-ups. From 1 March 2018 to 30 June 2018, a confidential rebate applied to the gross cost of Truvada. From 1 July 2018, the gross cost of Truvada does not include a confidential rebate. The number of patients refers to the total number of unique patients who have received funded Truvada for PrEP.

Truvada was [first funded for PrEP](#) from 1 March 2018. You can find the details of the funding restrictions for PrEP indication [here](#). Please note that it is also funded for the treatment of HIV, via endorsement. In instances where a patient has used Truvada for both PrEP and the treatment of HIV, they are counted under HIV indication (and not PrEP) and excluded from the table above.

We trust that the provision of this information answers your query, if you have any further questions please feel free to contact us again.

Yours sincerely



Alison Hill
Director, Engagement and Implementation